ProQR Therapeutics Future Growth
Future criteria checks 0/6
ProQR Therapeutics's revenue is forecast to decline at 7.1% per annum while its annual earnings are expected to grow at 2.2% per year. EPS is expected to grow by 16.5% per annum.
Key information
2.2%
Earnings growth rate
16.5%
EPS growth rate
Biotechs earnings growth | 0% |
Revenue growth rate | -7.1% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 07 Apr 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 13 | -32 | -16 | -21 | 4 |
12/31/2024 | 9 | -38 | -25 | -36 | 4 |
12/31/2023 | 27 | -12 | 25 | -32 | 7 |
12/31/2022 | 5 | -65 | -69 | -69 | N/A |
9/30/2022 | 4 | -72 | -48 | -47 | N/A |
6/30/2022 | 4 | -63 | -40 | -40 | N/A |
3/31/2022 | 4 | -63 | -35 | -35 | N/A |
12/31/2021 | 2 | -62 | -26 | -26 | N/A |
9/30/2021 | 2 | -57 | -42 | -42 | N/A |
6/30/2021 | 2 | -55 | -44 | -43 | N/A |
3/31/2021 | 1 | -43 | -45 | -44 | N/A |
12/31/2020 | 1 | -47 | -48 | -47 | N/A |
9/30/2020 | 1 | -52 | -48 | -47 | N/A |
6/30/2020 | 1 | -51 | -47 | -46 | N/A |
3/31/2020 | 2 | -58 | -47 | -47 | N/A |
12/31/2019 | 2 | -56 | -45 | -44 | N/A |
9/30/2019 | 3 | -51 | -41 | -41 | N/A |
6/30/2019 | 5 | -45 | -37 | -37 | N/A |
3/31/2019 | 6 | -40 | -32 | -31 | N/A |
12/31/2018 | 6 | -37 | -29 | -28 | N/A |
9/30/2018 | 4 | -35 | -28 | -28 | N/A |
6/30/2018 | 2 | -40 | -32 | -31 | N/A |
3/31/2018 | 1 | -44 | -36 | -36 | N/A |
12/31/2017 | 1 | -44 | -35 | -35 | N/A |
9/30/2017 | 1 | -41 | -34 | -34 | N/A |
6/30/2017 | 1 | -41 | -37 | -37 | N/A |
3/31/2017 | 1 | -39 | -37 | -35 | N/A |
12/31/2016 | 2 | -39 | -37 | -34 | N/A |
9/30/2016 | 3 | -36 | N/A | -34 | N/A |
6/30/2016 | 3 | -33 | N/A | -29 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRQR N is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRQR N is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRQR N is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRQR N's revenue is expected to decline over the next 3 years (-7.1% per year).
High Growth Revenue: PRQR N's revenue is forecast to decline over the next 3 years (-7.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRQR N's Return on Equity is forecast to be high in 3 years time